You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 9, 2025

Claims for Patent: 10,398,781

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,398,781

Title:	Conjugate based systems for controlled drug delivery
Abstract:	Conjugates which comprise a drug and a ligand which includes a first saccharide; wherein the conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic or pharmacodynamic property of the conjugate is sensitive to serum concentration of a second saccharide. Exemplary conjugates and sustained release formulations are provided in addition to methods of use and preparation.
Inventor(s):	Zion; Todd C. (Marblehead, MA), Lancaster; Thomas M. (Wenham, MA)
Assignee:	SMARTCELLS, INC. (Kenilworth, NJ)
Application Number:	15/680,262
Patent Claims:	1. A conjugate comprising an insulin molecule conjugated to one or more ligands that are independently selected from the group consisting of aminoethylglucose (AEG), aminoethylmannose (AEM), aminoethylbimannose (AEBM), aminoethyltrimannose (AETM), and .beta.-aminoethyl-N-acetylglucosamine (AEGA), wherein the one or more ligands are indirectly conjugated to the insulin molecule via a conjugate framework. 2. The conjugate of claim 1, wherein the insulin molecule is conjugated via the A1 amino acid residue, via the B1 amino acid residue, via the epsilon-amino group of Lys.sup.B29 or-via the epsilon-amino group of Lys.sup.B3. 3. The conjugate of claim 1, wherein the insulin molecule is conjugated to two or more separate ligands. 4. The conjugate of claim 3, wherein the two or more separate ligands are conjugated to a single conjugate framework that is also conjugated to the insulin molecule. 5. The conjugate of claim 3, wherein the two or more separate ligands and insulin molecule are each located on a separate branch of a single branched conjugate framework. 6. The conjugate of claim 5, wherein the two or more separate ligands and insulin molecule are each located on termini of separate branches of a single branched conjugate framework. 7. The conjugate of claim 3, wherein the two or more separate ligands are conjugated to the insulin molecule via two or more different conjugation points. 8. The conjugate of claim 7, wherein the insulin molecule is conjugated via the A1 amino acid residue and the epsilon-amino group of Lys.sup.B29. 9. The conjugate of claim 8, wherein the insulin molecule is conjugated to two separate conjugate frameworks that are each conjugated to one or more separate ligands. 10. The conjugate of claim 8, wherein the insulin molecule is conjugated to two separate branched conjugate frameworks that are each conjugated to two ligands. 11. The conjugate of claim 10, wherein the ligands are located on separate branches of the branched conjugate frameworks. 12. The conjugate of claim 11, wherein the ligands are located on termini of separate branches of the branched conjugate frameworks. 13. The conjugate of claim 3, wherein the two or more separate ligands are aminoethylglucose (AEG). 14. The conjugate of claim 3, wherein the two or more separate ligands are aminoethylmannose (AEM). 15. The conjugate of claim 3, wherein the two or more separate ligands are aminoethylbimannose (AEBM). 16. The conjugate of claim 3, wherein the two or more separate ligands are aminoethyltrimannose (AETM). 17. The conjugate of claim 3, wherein the two or more separate ligands are O-aminoethyl-N-acetylglucosamine (AEGA). 18. The conjugate of claim 1, wherein the insulin molecule is selected from the group consisting of human insulin, porcine insulin, and bovine insulin. 19. The conjugate of claim 1, wherein the insulin molecule is selected from the group consisting of insulin lispro, insulin aspart, and insulin glulisine. 20. The conjugate of claim 1, wherein the insulin molecule is insulin glargine or insulin detemir.

Details for Patent 10,398,781

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563	June 14, 1996	10,398,781	2029-01-28
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563	August 06, 1998	10,398,781	2029-01-28
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563	September 06, 2007	10,398,781	2029-01-28
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563	June 06, 2017	10,398,781	2029-01-28
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563	November 15, 2019	10,398,781	2029-01-28
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.